HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $6
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.
